Clinical Trials Logo

Clinical Trial Summary

The hypothesis is growing semen samples with plasma rich in growth factors (PRGF), because it could improve sperm motility in patients subsidiary TRA, ultimately improving pregnancy rates.


Clinical Trial Description

Platelet growth factors are a group of proteins involved in cellular communication modifying biological responses. Obtaining plasma rich in growth factors is already widespread and simple protocol technique that is being used in various areas of medicine with superb results. Described many of the growth factors present in the PRGF are related to sperm parameters, especially motility The described effects have been studied in mammalian and each growth factor individually. PRGF contains a pool of growth factors and therefore be interesting to analyze their effect on various sperm parameters. One of those parameters is very important for fertilization sperm motility, since the lack of it will prevent displacement by the cervix to meet the egg in the fallopian tube. ;


Study Design


Related Conditions & MeSH terms

  • Vascular Endothelial Growth Factor Overexpression

NCT number NCT02708537
Study type Observational
Source IVI Bilbao
Contact
Status Completed
Phase
Start date April 2016
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT02168322 - Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels N/A
Terminated NCT04991350 - Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema Phase 4
Completed NCT04970251 - Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma N/A
Completed NCT04674254 - Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy Phase 4
Completed NCT00848185 - Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Completed NCT02447679 - Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence Phase 2
Recruiting NCT03648814 - Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT N/A